A temporal (phospho-)proteomic dataset of neurotrophic receptor tyrosine kinase signalling in neuroblastoma.
Journal
Scientific data
ISSN: 2052-4463
Titre abrégé: Sci Data
Pays: England
ID NLM: 101640192
Informations de publication
Date de publication:
10 Oct 2024
10 Oct 2024
Historique:
received:
07
08
2024
accepted:
02
10
2024
medline:
11
10
2024
pubmed:
11
10
2024
entrez:
10
10
2024
Statut:
epublish
Résumé
Neurotrophic receptor tyrosine kinases (TrkA, TrkB, TrkC), despite their homology, contribute to the clinical heterogeneity of the childhood cancer neuroblastoma. TrkA expression is associated with low-stage disease and is often seen with spontaneous tumour regression. Conversely, TrkB is present in unfavourable neuroblastomas that often harbour amplification of the MYCN oncogene. The role of TrkC is less clearly defined, although some studies suggest its association with a favourable outcome. Understanding the differences in activity of Trk receptors that drive divergent clinical phenotypes as well as the influence of MYCN amplification on downstream Trk receptor signalling remains poorly understood. Here, we present a comprehensive label-free mass spectrometry-based total proteomics and phosphoproteomics dataset (432 raw files with FragPipe search outputs; available on PRIDE with accession number PXD054441) where we identified and quantified 4,907 proteins, 16,744 phosphosites and 5,084 phosphoproteins, derived from NGF/BDNF/NT-3 treated TrkA/B/C-overexpressing neuroblastoma cells with differential MYCN status. Analysing our dataset offers valuable insights into TrkA/B/C receptor signalling in neuroblastoma and its modulation by MYCN status; and holds potential for advancing therapeutic strategies in this challenging childhood cancer.
Identifiants
pubmed: 39389992
doi: 10.1038/s41597-024-03965-y
pii: 10.1038/s41597-024-03965-y
doi:
Substances chimiques
Receptor, trkA
EC 2.7.10.1
Receptor, trkC
EC 2.7.10.1
N-Myc Proto-Oncogene Protein
0
Receptor, trkB
EC 2.7.10.1
Phosphoproteins
0
NTRK1 protein, human
0
MYCN protein, human
0
Types de publication
Dataset
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1111Subventions
Organisme : Irish Research Council (An Chomhairle um Thaighde in Éirinn)
ID : GOIPG/2020/1361
Organisme : Science Foundation Ireland (SFI)
ID : 18/SPP/3522
Organisme : Science Foundation Ireland (SFI)
ID : 18/RI/5702
Informations de copyright
© 2024. The Author(s).
Références
Barbacid, M. The Trk family of neurotrophin receptors. J. Neurobiol. 25, 1386–1403 (1994).
doi: 10.1002/neu.480251107
Huang, E. J. & Reichardt, L. F. Trk receptors: roles in neuronal signal transduction. Annu. Rev. Biochem. 72, 609–642 (2003).
doi: 10.1146/annurev.biochem.72.121801.161629
Bartkowska, K., Paquin, A., Gauthier, A. S., Kaplan, D. R. & Miller, F. D. Trk signaling regulates neural precursor cell proliferation and differentiation during cortical development. Dev. Camb. Engl. 134, 4369–4380 (2007).
Brodeur, G. M. et al. Expression of TrkA, TrkB and TrkC in human neuroblastomas. J. Neurooncol. 31, 49–56 (1997).
doi: 10.1023/A:1005729329526
Eggert, A., Ikegaki, N., Liu, X. G. & Brodeur, G. M. Prognostic and biological role of neurotrophin-receptor TrkA and TrkB in neuroblastoma. Klin. Padiatr. 212, 200–205 (2000).
doi: 10.1055/s-2000-9677
Amatu, A. et al. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann. Oncol. 30, viii5–viii15 (2019).
doi: 10.1093/annonc/mdz383
Gupta, V. K., You, Y., Gupta, V. B., Klistorner, A. & Graham, S. L. TrkB receptor signalling: implications in neurodegenerative, psychiatric and proliferative disorders. Int. J. Mol. Sci. 14, 10122–10142 (2013).
doi: 10.3390/ijms140510122
Brodeur, G. M. Spontaneous regression of neuroblastoma. Cell Tissue Res. 372, 277–286 (2018).
doi: 10.1007/s00441-017-2761-2
Matthay, K. K. et al. Neuroblastoma. Nat. Rev. Dis. Primer 2, 16078 (2016).
doi: 10.1038/nrdp.2016.78
Rukhlenko, O. S. et al. Control of cell state transitions. Nature 609, 975–985 (2022).
doi: 10.1038/s41586-022-05194-y
Kogner, P. et al. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res. 53, 2044–2050 (1993).
Nakagawara, A., Arima, M., Azar, C. G., Scavarda, N. J. & Brodeur, G. M. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res. 52, 1364–1368 (1992).
Suzuki, T., Bogenmann, E., Shimada, H., Stram, D. & Seeger, R. C. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J. Natl. Cancer Inst. 85, 377–384 (1993).
doi: 10.1093/jnci/85.5.377
Nakagawara, A. et al. Association between High Levels of Expression of the TRK Gene and Favorable Outcome in Human Neuroblastoma. N. Engl. J. Med. 328, 847–854 (1993).
doi: 10.1056/NEJM199303253281205
Nakagawara, A. & Brodeur, G. M. Role of neurotrophins and their receptors in human neuroblastomas: a primary culture study. Eur. J. Cancer 33, 2050–2053 (1997).
doi: 10.1016/S0959-8049(97)00280-3
Combaret, V. et al. Clinical relevance of TRKA expression on neuroblastoma: comparison with N-MYC amplification and CD44 expression. Br. J. Cancer 75, 1151–1155 (1997).
doi: 10.1038/bjc.1997.198
Matsumoto, K., Wada, R. K., Yamashiro, J. M., Kaplan, D. R. & Thiele, C. J. Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res. 55, 1798–1806 (1995).
Nakamura, K. et al. Brain-derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma cells. Cancer Res. 66, 4249–4255 (2006).
doi: 10.1158/0008-5472.CAN-05-2789
Jaboin, J., Kim, C. J., Kaplan, D. R. & Thiele, C. J. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3′-kinase pathway. Cancer Res. 62, 6756–6763 (2002).
Acheson, A. et al. A BDNF autocrine loop in adult sensory neurons prevents cell death. Nature 374, 450–453 (1995).
doi: 10.1038/374450a0
Ho, R. et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res. 62, 6462–6466 (2002).
Nakagawara, A., Azar, C. G., Scavarda, N. J. & Brodeur, G. M. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol. Cell. Biol. 14, 759–767 (1994).
Edsjö, A. et al. Expression of trkB in Human Neuroblastoma in Relation to MYCN Expression and Retinoic Acid Treatment. Lab. Invest. 83, 813–823 (2003).
doi: 10.1097/01.LAB.0000074895.48776.D8
Rydén, M. et al. Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis. Br. J. Cancer 74, 773–779 (1996).
doi: 10.1038/bjc.1996.435
Yamashiro, D. J. et al. Expression and function of Trk-C in favourable human neuroblastomas. Eur. J. Cancer Oxf. Engl. 1990 33, 2054–2057 (1997).
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E. & Bishop, J. M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224, 1121–1124 (1984).
doi: 10.1126/science.6719137
Yue, Z.-X. et al. MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma. Cancer Cell Int. 17, 43 (2017).
doi: 10.1186/s12935-017-0412-z
Tjaden, B. et al. N-Myc-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastoma. Sci. Rep. 10, 7157 (2020).
doi: 10.1038/s41598-020-64040-1
Kang, J.-H. et al. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem. Biophys. Res. Commun. 351, 192–197 (2006).
doi: 10.1016/j.bbrc.2006.10.020
Zaatiti, H. et al. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration. Int. J. Oncol. 52, 787–803 (2018).
Raieli, S. et al. MYCN Drives a Tumor Immunosuppressive Environment Which Impacts Survival in Neuroblastoma. Front. Oncol. 11, 625207 (2021).
doi: 10.3389/fonc.2021.625207
Duffy, D. J. et al. Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma. Oncotarget 6, 43182–43201 (2015).
doi: 10.18632/oncotarget.6568
Maher, S, Wynne, K, Zhernovkov, V, Halasz, M. MYCN blocks TRKC mediated differentiatio in neuroblastoma cells via disruption of the PKA signalling pathway. bioRxiv 2024.08.07.606961; https://doi.org/10.1101/2024.08.07.606961 (2024).
Harenza, J. L. et al. Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. Sci. Data 4, 1–9 (2017).
Kolch, W., Halasz, M., Granovskaya, M. & Kholodenko, B. N. The dynamic control of signal transduction networks in cancer cells. Nat. Rev. Cancer 15, 515–527 (2015).
doi: 10.1038/nrc3983
Kholodenko, B. N. Cell-signalling dynamics in time and space. Nat. Rev. Mol. Cell Biol. 7, 165–176 (2006).
doi: 10.1038/nrm1838
Yang, X. et al. A public genome-scale lentiviral expression library of human ORFs. Nat. Methods 8, 659–661 (2011).
doi: 10.1038/nmeth.1638
Meier, F. et al. Online Parallel Accumulation-Serial Fragmentation (PASEF) with a Novel Trapped Ion Mobility Mass Spectrometer. Mol. Cell. Proteomics MCP 17, 2534–2545 (2018).
doi: 10.1074/mcp.TIR118.000900
Yu, F. et al. Fast Quantitative Analysis of timsTOF PASEF Data with MSFragger and IonQuant. Mol. Cell. Proteomics MCP 19, 1575–1585 (2020).
doi: 10.1074/mcp.TIR120.002048
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
doi: 10.1093/nar/gkv007
Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543–D552 (2022).
doi: 10.1093/nar/gkab1038
Temporal (phospho-)proteomic profiling of neurotrophic receptor tyrosine kinase signalling in neuroblastoma cells. PRIDE. Accession number: PXD054441. https://identifiers.org/pride.project:PXD054441 (2024).
Maher, S., Wynne, K., Zhernovkov, V. & Halasz, M. Temporal (phospho-)proteomic profiling of neurotrophic receptor tyrosine kinase signalling in neuroblastoma cells. Figshare. https://doi.org/10.6084/m9.figshare.26863267 (2024).